Abbisko Cayman Limited
Research Abbisko Cayman Limited (2256.HK) on Bullrun: market cap HKD 5.55B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker2256.HK
- ExchangeHK
- CountryChina
- SectorHealthcare
- IndustryBiotechnology
- CurrencyHKD
- Market capHKD 5.55B
- Financial periodFY2025
- RevenueCNY 612.12M
- Revenue growth21.5%
- Net incomeCNY 55.25M
- Free cash flowCNY 73.75M
- Gross margin100.0%
Valuation Snapshot
latest market cap is HKD 5.55B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | CNY 612.12M | CNY 55.25M | CNY 73.75M | 100.0% | 0.09 | CNY 749.01M | CNY 303.48M | CNY 1.92B |
| FY2024 | CNY 503.99M | CNY 28.30M | -CNY 20.32M | 100.0% | 0.04 | CNY 289.53M | CNY 24.29M | CNY 1.96B |
| FY2023 | CNY 19.06M | -CNY 431.58M | -CNY 456.98M | 100.0% | -0.67 | CNY 578.08M | CNY 35.72M | CNY 1.98B |
| FY2022 | CNY 0 | -CNY 495.61M | -CNY 366.64M | n/a | -0.8 | CNY 641.84M | CNY 45.58M | CNY 2.35B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | HKD 5.55B | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 HKD.
About Abbisko Cayman Limited
Abbisko Cayman Limited, together with its subsidiaries, engages in the research, discovery, and development of pharmaceutical products in Mainland China and the European Union. The company develops Pimicotinib (ABSK021), a small molecule CSF-1R inhibitor, which is in NDA/commercial stage for the treatment of tenosynovial giant cell tumors and Phase Ib/II for the treatment of chronic graft versus host disease;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Abbisko Cayman Limited's market cap?
Abbisko Cayman Limited's market capitalization is HKD 5.55B.
What does Abbisko Cayman Limited do?
Abbisko Cayman Limited, together with its subsidiaries, engages in the research, discovery, and development of pharmaceutical products in Mainland China and the European Union. The company develops Pimicotinib (ABSK021), a small molecule CSF-1R inhibitor, which is in NDA/commercial stage for the treatment of tenosynovial giant cell tumors and Phase Ib/II for the treatment of chronic graft versus host disease; and Irpagratinib (ABSK011), a small-molecule inhibitor of FGFR4, which is in pivotal stage and Phase Ib/II for the treatment of hepatocellular carcinoma.